All In Biotech

NDA 020375 · Bayer Hlthcare

Climara

Estradiol · Transdermal · Estrogen

Last checked: Nov 19, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Dec 22, 1994

Approved uses

3

Original approval plus efficacy supplements

Registered trials

1,701

351 Phase 3, 176 recruiting

FAERS reports

57,593

24,115 serious, 958 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA and BREAST CANCER Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated to rule out malignancy in postmenopausal women with undiagnosed, persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2) ] . Cardiovascular Disorders and Probable Dementia The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment...

What it is approved for

From the label in effect Mar 26, 2026.

Climara is indicated for: Climara is an estrogen indicated for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) Limitations of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) Prevention of Postmenopausal Osteoporosis ( 1.4 ) Limitations of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration, or Primary Ovarian Failure 1.4 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.

Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 5, 2001 Supplement 16 · Efficacy ReviewLetterLabel
  • Apr 11, 1997 Supplement 6 · Efficacy
  • Dec 22, 1994 Original approval · Type 5 - New Formulation or New Manufacturer
7 products under this application
  • CLIMARA · ESTRADIOL 0.06MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB2
  • CLIMARA · ESTRADIOL 0.025MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB2
  • CLIMARA · ESTRADIOL 0.1MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB2
  • MENOSTAR · ESTRADIOL 0.014MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • CLIMARA · ESTRADIOL 0.0375MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB2
  • CLIMARA · ESTRADIOL 0.075MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB2
  • CLIMARA · ESTRADIOL 0.05MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.

All 1,701 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product adhesion issue5,459
  • drug ineffective5,040
  • headache3,312
  • nausea3,167
  • fatigue3,124
  • off label use2,704
  • hot flush2,356
  • pain2,237
  • diarrhoea2,071
  • dizziness1,911
  • breast cancer female1,833
  • rash1,825

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004612
2005703
2006535
20071,547
20081,032
2009864
20101,164
20111,184
20121,414
20131,075
20141,321
20152,351
20162,855
20172,725
20183,011
20193,511
20203,484
20213,486
20223,548
20234,070
20244,307
20256,292
20266,501

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Climara (Estradiol)

2024 spending

$3.1M

Beneficiaries

6,878

22,120 claims

Per beneficiary

$447

$13.21 per unit

View as table
YearSpending
2020$5,869,463
2021$5,690,657
2022$4,658,567
2023$3,683,131
2024$3,071,054

Part D: Menostar (Estradiol)

2024 spending

$605K

Beneficiaries

432

1,679 claims

Per beneficiary

$1,401

$38.76 per unit

View as table
YearSpending
2020$704,281
2021$685,540
2022$651,121
2023$611,837
2024$605,353

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,473 on PubMed

Sponsor: Bayer · Also marketed as Menostar

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.